This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® Serotypes matterBurden of diseaseIPDCAPPatient profilesPatient
profilesAge 50+: Arlene, Age 51Diabetes: David, Age 46Asthma: Carly, Age 30COPD: William, Age 48Age 65+: Tyrell, Age 67 Risk for All Underlying Medical ConditionsMary, 65: Healthy ≥65; Unknown Vaccination HistoryCDC recommendationsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyAdministrationAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideosEvents
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
Clinical studiesCAPiTA: Community-Acquired Pneumonia Immunization Trial in AdultsPrevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) was evaluated in a landmark trial of nearly 85,000 participants1-3
Scroll left to view table
Scroll left to view table
CAPiTA Study end points
Adults age 65 or older Primary
  • A double-blind, randomized, parallel-group, placebo-controlled vaccine efficacy trial 
  • 84,496 immunocompetent adults aged 65 or older
  • 59 sites throughout the Netherlands conducted surveillance 
  • 3.93 years—median duration of follow-up
  • Prevention of a first episode of confirmed vaccine-type CAP and a positive vaccine-type specific urinary antigen test or isolation of vaccine-type Streptococcus pneumoniae from blood or another sterile site
Adults were excluded if they Secondary
  • Had immunocompromising conditions
  • Received immunosuppressive therapy
  • Resided in a long-term care facility
  • Required semi-skilled nursing care
  • Prevention of a first episode of vaccine-type CAP for which the result of a blood culture and results of cultures of any other sterile site were negative for S. pneumoniae
  • Prevention of a first episode of vaccine-type IPD in which the presence of S. pneumoniae was detected in a sterile site
Prevnar 13 was evaluated in CAPiTA, a landmark clinical trial1,2,4

~85,000 adults aged 65 or older participated in CAPiTA1,2,4

Primary end point2:

(95.2% CI, 21.8-62.5) of a first episode of either vaccine-type nonbacteremic/noninvasive or vaccine-type bacteremic/invasive pneumococcal CAP (number of episodes: Prevnar 13 n=49; placebo n=90)Primary end point2:

Secondary end points2:
statistically significant RISK REDUCTION

(95.2% CI, 14.2-65.3) of a first episode of vaccine-type nonbacteremic/noninvasive pneumococcal CAP (Number of episodes: Prevnar 13 n=33; placebo n=60)

 statistically significant RISK REDUCTION

(95% CI, 41.4-90.8) of a first episode of vaccine-type IPD (Number of episodes: Prevnar 13 n=7; placebo n=28)

SAFETY PROFILE FOR ADULTS IN THE CAPiTA STUDY1,3
Scroll left to view table
Local adverse events (%) PCV13
(n=886-914*)		 Placebo
(n=859-865*)
Pain (any) 36.1† 6.1
Limitation of arm movement (any) 14.1† 3.2
Swelling (any) 6.8† 1.2
Redness (any) 4.9† 1.2
Scroll left to view table
Incidence of fever (%) PCV13
(n=881-896*)		 Placebo
(n=860-878*)
≥100.4 °F 2.9† 1.3
100.4-101.1 °F 1.1 0.6
101.2-102.0 °F 0.6 0.2
102.1-104.0 °F 0.7 0.2
>104.0 °F 0.8 0.3
Scroll left to view table
Systemic adverse events (%) PCV13
(n=881-896*)		 Placebo
(n=860-878*)
Fatigue 18.8† 14.8
New muscle pain‡ 18.4† 8.4
Headache 15.9 14.8
Chills 9.4 8.4
Aggravated muscle pain‡ 9.1† 4.4
New joint pain‡ 7.4 5.4
Decreased appetite 5.3 3.7
Aggravated joint pain‡ 5.2 4.2
Rash 5.2 0.8
Vomiting 5.2 0.9
 

From the CAPiTA study, for a subset of 2011 subjects (1006 PCV13 and 1005 placebo recipients), solicited adverse reactions were monitored by recording local and systemic events using electronic diaries for 7 days after vaccination. Unsolicited adverse events were collected for 28 days after vaccination.1

Prevnar 20® real-world effectiveness study Learn more Loading CAP=community-acquired pneumonia; CI=confidence interval; IPD=invasive pneumococcal disease; PCV13=13-valent pneumococcal conjugate vaccine.Prevnar 13 will only help protect against Streptococcus pneumoniae serotypes in the vaccine.1*Number of patients with known values.†P<0.05. No adjustments for multiplicity.​​‡Generalized pain.References: Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125.Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults: Supplementary appendix. N Engl J Med. 2015;372(11):1-74.Prevnar 20 ® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2023. Clinical studies With 20 serotypes in its pneumococcal conjugate vaccine, you can help protect your eligible adult patients 4
Explore additional protection
Loading Order Prevnar 20 for your office by registering for Prime Get startedLoading CAP=community-acquired pneumonia; CI=confidence interval; IPD=invasive pneumococcal disease; PCV13=13-valent pneumococcal conjugate vaccine.Prevnar 13 will only help protect against Streptococcus pneumoniae serotypes in the vaccine.1*Number of patients with known values. †P<0.05. No adjustments for multiplicity.‡Generalized pain.References: Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125.Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults: Supplementary appendix. N Engl J Med. 2015;372(11):1-74.Prevnar 20 ® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2023.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-2559 © 2025 Pfizer Inc.
All rights reserved. January 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2559
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20® in individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.INDICATIONS
  • Prevnar 20® is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is indicated for active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine